News

Immuneering Shares Promising Data on Pancreatic Cancer Treatment

Immuneering Shares Promising Data on Pancreatic Cancer Treatment

Immuneering Corporation Unveils New Data on Pancreatic Cancer Trials

- Company to hold an investor call on upcoming data -

- Presentation at PanCAN Scientific Summit following data release -

- Deep Cyclic Inhibitors to be reviewed at the RAS-Targeted Drug Development Summit -

CAMBRIDGE, Mass. — Immuneering Corporation (NASDAQ: IMRX) is making strides in the oncology field with its focus on keeping cancer patients alive. The company recently announced its plans to share updated overall survival data from a phase 2a clinical trial involving patients with first-line pancreatic cancer, treated with atebimetinib in combination with modified Gemcitabine/nab-paclitaxel (mGnP).

The upcoming presentation is set to take place on a Thursday following the announcement, with recent data reflecting a median follow-up of nine months involving 34 patients in the trial. This reveal is crucial, especially considering that pancreatic cancer patients face low survival rates with traditional treatments.

Upcoming Presentations and Insights

Immuneering’s commitment to transparency and scientific collaboration is evident in their presentation plans:

Investor Call on September 25

The first key event is an investor call scheduled for 8 a.m. ET where Immuneering will discuss the updated survival data and its implications in the context of pancreatic cancer treatment. This call will be available via a live webcast, allowing stakeholders and interested parties to stay informed.

PanCAN Scientific Summit Presentation

Directly following the investor call, Immuneering will present a poster titled "Atebimetinib + mGnP: Overall Survival and Safety in First-Line Pancreatic Cancer Patients” at the PanCAN Scientific Summit 2025. This summit, aimed at enhancing understanding and treatment of pancreatic cancer, represents a significant opportunity for the company to showcase its findings to healthcare professionals and researchers.

Insights on Preclinical Data

In addition to the aforementioned presentations, Immuneering will also share compelling preclinical data regarding Deep Cyclic Inhibitors at the RAS-Targeted Drug Development Summit. The discussion will emphasize how these novel inhibitors represent a transformative approach in treating RAS-mutant cancers.

According to Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering, the team is eager to share these results. "We are excited to share updated overall survival data from our ongoing Phase 2a trial. Our previous reports have indicated a remarkable 94% overall survival at the six-month mark with the atebimetinib + mGnP regimen. This is substantial when considering that only about 47% survive to nine months with traditional therapies like Gemcitabine/nab-paclitaxel."

Zeskind elaborated on the potential of atebimetinib, highlighting its design for durability, tolerability, and improved patient outcomes. Immuneering aims to shift the paradigm in pancreatic cancer care by addressing common shortcomings found in current treatment options.

About Immuneering Corporation

Immuneering is pioneering a unique category of cancer treatments with its Deep Cyclic Inhibitors, targeting pathways crucial for tumor survival. The lead candidate, atebimetinib (IMM-1-104), demonstrates promising results in improving the treatment landscape for pancreatic cancers.

As the clinical trials for this innovative drug continue to unfold, Immuneering's pipeline remains robust, focusing on early-stage programs alongside its main candidates. Stakeholders and interested parties can visit www.immuneering.com for further information on their research and clinical endeavors.

Frequently Asked Questions

What is Immuneering Corporation known for?

Immuneering Corporation is a clinical-stage oncology company focused on developing innovative cancer treatments, particularly through its unique Deep Cyclic Inhibitors.

When is the investor call taking place?

The investor call is scheduled for 8 a.m. ET, shortly before the updated survival data will be shared.

What are Deep Cyclic Inhibitors?

Deep Cyclic Inhibitors represent a new category of cancer medicines developed by Immuneering, aimed at enhancing treatment durability and tolerability.

Where will Immuneering present its findings?

Immuneering will present its findings at the PanCAN Scientific Summit and the RAS-Targeted Drug Development Summit.

How can I find more information about Immuneering’s clinical trials?

More details about their clinical trials and ongoing research can be found on the company’s official website, www.immuneering.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 67

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading
Tigo's Guidance Gap Draws Lawsuit and Investor Scrutiny

Updated Category News Views 84

A Revenue Promise Hit the Wall Solar investing can turn ugly in a hurry when a supposedly near-term catalyst gets shoved down the calendar. That is the central bruise behind the securities class action involving Tigo Energy, not some arcane accounting footnote that only lawyers can love. The complaint alleges Tigo overstated the revenue contribution it expected from its...

Continue Reading
Perigon Builds Its Investment Bench for the Next Leg

Updated Category News Views 110

Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...

Continue Reading
1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 39

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading

Top 5 Most Recently Viewed Articles

Constellation Brands Innovates with New Wine Portfolio Focus

Updated Category News Views 254

Constellation Brands Completes Transaction with The Wine Group ROCHESTER, N.Y. — Constellation Brands (NYSE: STZ), a prominent player in the beverage alcohol industry, has officially finalized its transaction with The Wine Group, marking a significant shift in its wine strategy. By divesting mainstream wine brands and associated assets, Constellation aims to concentrate...

Continue Reading
GomSpace North America Secures Major USD 1.5 Million Order

Updated Category News Views 198

Exciting Order Announcement from GomSpace North America GomSpace North America, a subsidiary of GomSpace Group AB, has successfully secured a major order valued at USD 1.5 million. This contract, which underscores the growing trust in GomSpace's advanced technological solutions, involves supplying key components aimed at supporting an upcoming satellite mission. Details...

Continue Reading
Venice Comprehensive Dentistry's Evolution: A New Era of Care

Updated Category News Views 169

Venice Comprehensive Dentistry's Transformation Venice Comprehensive Dentistry, previously known as Florida Dental Implant Center, has officially announced a significant rebranding aimed at better reflecting the diverse range of dental services it now offers. This exciting change marks a pivotal moment in the practice's journey, emphasizing its commitment to comprehensive...

Continue Reading
Important Insights from ABC Arbitrage's Upcoming General Meeting

Updated Category News Views 183

Understanding ABC Arbitrage's General Meeting ABC arbitrage is gearing up for a significant event as it prepares for its upcoming Combined General Meeting. Scheduled at a centrally located venue, this meeting promises to provide shareholders with essential insights into the company’s direction. Meeting Details and Important Dates The Combined General Meeting of ABC...

Continue Reading
Arrowpoint Investment Partners Selects SS&C for Fund Services

Updated Category News Views 291

Arrowpoint Investment Partners Chooses SS&C for Fund Management Arrowpoint Investment Partners, a newly established multi-strategy hedge fund investment firm, has made a significant move in the evolving financial services landscape by selecting SS&C GlobeOp for the administration of its flagship investment fund, valued at $1 billion. This decision highlights the firm’s...

Continue Reading